You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriamterene
Accession NumberDB00384  (APRD00079)
TypeSmall Molecule
GroupsApproved
DescriptionA pteridine that is used as a mild diuretic. [PubChem]
Structure
Thumb
Synonyms
6-phenylpteridine-2,4,7-triamine
Dyrenium
Teridin
Triamteren
Triamtérène
Triamterene
Triamtereno
Triamterenum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dyreniumcapsule50 mg/1oralConcordia Pharmaceuticals Inc.1999-10-01Not applicableUs
Dyreniumcapsule50 mg/1oralCarilion Materials Management1999-10-01Not applicableUs
Dyreniumcapsule100 mg/1oralConcordia Pharmaceuticals Inc.1999-01-01Not applicableUs
Dyreniumcapsule50 mg/1oralWell Spring Pharmaceutical Corporation1999-10-01Not applicableUs
Dyreniumcapsule100 mg/1oralWell Spring Pharmaceutical Corporation1999-01-01Not applicableUs
Dyrenium 100tablet100 mgoralGlaxosmithkline Inc1992-12-312002-07-03Canada
Dyrenium 50tablet50 mgoralGlaxosmithkline Inc1992-12-312002-07-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiuterenKotobuki Seiyaku
DytacMercury
RiyazineCiiphar
TriterenKyoto Yakuhin
UrinisYing Yuan
Brand mixtures
NameLabellerIngredients
Apo TriazideApotex Inc
DyazideGlaxo Smith Kline Llc
Dyazide TabSmithkline Beecham Pharma Division Of Smithkline Beecham Inc
MaxzideMylan Pharmaceuticals Inc.
Maxzide-25Mylan Pharmaceuticals Inc.
Nu-triazide Tab 50 Mg/25 mgNu Pharm Inc
Penta-triamterene Hctz TabletsPentapharm Ltd.
Pro-triazidePro Doc Limitee
Riva-zide 50/25mg TabletsLaboratoire Riva Inc
Teva-triamterene/hctzTeva Canada Limited
Triamterene and HydrochlorothiazideKAISER FOUNDATION HOSPITALS
Triamterene HydrochlorothiazideKAISER FOUNDATION HOSPITALS
SaltsNot Available
Categories
UNIIWS821Z52LQ
CAS number396-01-0
WeightAverage: 253.2626
Monoisotopic: 253.107593387
Chemical FormulaC12H11N7
InChI KeyInChIKey=FNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
IUPAC Name
6-phenylpteridine-2,4,7-triamine
SMILES
NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form pyrimido(4,5-b)pyrazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPteridines and derivatives
Sub ClassNot Available
Direct ParentPteridines and derivatives
Alternative Parents
Substituents
  • Pteridine
  • Aminopyrimidine
  • Aminopyrazine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Pyrazine
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.
PharmacodynamicsTriamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.
Mechanism of actionTriamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.
Related Articles
AbsorptionRapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
Volume of distributionNot Available
Protein binding55-67% (93% for the OH-TA-ester metabolite)
Metabolism

Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.

Route of eliminationNot Available
Half life255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.
Clearance
  • 4.5 l/min [total plasma clearance]
  • 0.22 l/kg [renal plasma clearance]
ToxicityIn the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Triamterene Action PathwayDrug actionSMP00132
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8735
Caco-2 permeable+0.7017
P-glycoprotein substrateNon-substrate0.6269
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8437
CYP450 2C9 substrateNon-substrate0.8949
CYP450 2D6 substrateNon-substrate0.8892
CYP450 3A4 substrateNon-substrate0.7542
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6161
Ames testNon AMES toxic0.8934
CarcinogenicityNon-carcinogens0.9092
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.7706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wellspring pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Capsuleoral100 mg/1
Capsuleoral50 mg/1
Tabletoral100 mg
Tabletoral50 mg
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point316 °CPhysProp
water solubility48.2 mg/LNot Available
logP0.98HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.963 mg/mLALOGPS
logP1.21ALOGPS
logP1.11ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)3.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity75.13 m3·mol-1ChemAxon
Polarizability25.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - CI-B (Unknown) , Positivesplash10-0udi-0090000000-c8bbcf103f5a3fdfebb5View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Frederic J. Nugent, John K. C. Yen, “Process for preparing the combination products of triamterene and hydrochlorothiazide.” U.S. Patent US4804540, issued July, 1987.

US4804540
General References
  1. Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. [PubMed:6628507 ]
External Links
ATC CodesC03DB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Triamterene can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Triamterene.
AcetazolamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Acetazolamide.
AcetyldigitoxinThe therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Triamterene.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Triamterene.
AdapaleneAdapalene may decrease the antihypertensive activities of Triamterene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triamterene.
AliskirenThe risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Triamterene.
AmilorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Amiloride.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Triamterene.
Ammonium chlorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Ammonium chloride.
AmobarbitalAmobarbital may increase the hypotensive activities of Triamterene.
Amyl NitriteThe risk or severity of adverse effects can be increased when Triamterene is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Triamterene.
ApraclonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Triamterene.
ArdeparinArdeparin may increase the hyperkalemic activities of Triamterene.
AripiprazoleAripiprazole may increase the hypotensive activities of Triamterene.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Triamterene.
AzelastineAzelastine may decrease the antihypertensive activities of Triamterene.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Triamterene is combined with Azilsartan medoxomil.
AzithromycinThe metabolism of Triamterene can be decreased when combined with Azithromycin.
BalsalazideBalsalazide may decrease the antihypertensive activities of Triamterene.
BarbitalBarbital may increase the hypotensive activities of Triamterene.
BemiparinBemiparin may increase the hyperkalemic activities of Triamterene.
BenazeprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Benazepril.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Bendroflumethiazide.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Triamterene.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Triamterene.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Triamterene.
BisoprololThe risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.
BortezomibThe metabolism of Triamterene can be decreased when combined with Bortezomib.
BretyliumThe risk or severity of adverse effects can be increased when Triamterene is combined with Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Brimonidine.
BromfenacBromfenac may decrease the antihypertensive activities of Triamterene.
BumetanideThe risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.
CaffeineThe metabolism of Triamterene can be decreased when combined with Caffeine.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Triamterene.
CanagliflozinThe risk or severity of adverse effects can be increased when Triamterene is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Candesartan.
CandoxatrilTriamterene may increase the hyperkalemic activities of Candoxatril.
CaptoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Captopril.
CarbamazepineThe metabolism of Triamterene can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Triamterene.
CarprofenCarprofen may decrease the antihypertensive activities of Triamterene.
CarteololThe risk or severity of adverse effects can be increased when Triamterene is combined with Carteolol.
CarvedilolThe risk or severity of adverse effects can be increased when Triamterene is combined with Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Triamterene.
CelecoxibCelecoxib may decrease the antihypertensive activities of Triamterene.
CertoparinCertoparin may increase the hyperkalemic activities of Triamterene.
ChloroquineChloroquine may decrease the antihypertensive activities of Triamterene.
ChlorothiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Triamterene.
CilazaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilazapril.
CitalopramThe metabolism of Triamterene can be decreased when combined with Citalopram.
ClevidipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.
ClonidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Clonidine.
ClonixinClonixin may decrease the antihypertensive activities of Triamterene.
ClotrimazoleThe metabolism of Triamterene can be decreased when combined with Clotrimazole.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.
CyclosporineTriamterene may increase the hyperkalemic activities of Cyclosporine.
Cyproterone acetateThe serum concentration of Triamterene can be decreased when it is combined with Cyproterone acetate.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Triamterene.
DalteparinDalteparin may increase the hyperkalemic activities of Triamterene.
DapagliflozinThe risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.
DeferasiroxThe serum concentration of Triamterene can be increased when it is combined with Deferasirox.
DeslanosideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.
DexmedetomidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Triamterene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Triamterene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Triamterene.
DiclofenacDiclofenac may decrease the antihypertensive activities of Triamterene.
DiclofenamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Triamterene.
DigitoxinThe therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene.
DigoxinThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Triamterene.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Triamterene.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Triamterene.
DinutuximabThe risk or severity of adverse effects can be increased when Triamterene is combined with Dinutuximab.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Triamterene.
DipyridamoleThe risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Triamterene.
DoxazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Triamterene.
DrospirenoneDrospirenone may increase the hyperkalemic activities of Triamterene.
DroxicamDroxicam may decrease the antihypertensive activities of Triamterene.
DuloxetineTriamterene may increase the orthostatic hypotensive activities of Duloxetine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Enalapril.
EnalaprilatTriamterene may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Triamterene.
EpirizoleEpirizole may decrease the antihypertensive activities of Triamterene.
EplerenoneThe risk or severity of adverse effects can be increased when Triamterene is combined with Eplerenone.
EprosartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Eprosartan.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Triamterene.
Etacrynic acidThe risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Triamterene.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Triamterene.
EtodolacEtodolac may decrease the antihypertensive activities of Triamterene.
EtofenamateEtofenamate may decrease the antihypertensive activities of Triamterene.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Triamterene.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Triamterene.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Triamterene.
exisulindexisulind may decrease the antihypertensive activities of Triamterene.
FelodipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Triamterene.
FenoprofenFenoprofen may decrease the antihypertensive activities of Triamterene.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.
FloctafenineFloctafenine may decrease the antihypertensive activities of Triamterene.
FlunixinFlunixin may decrease the antihypertensive activities of Triamterene.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Triamterene.
FluvoxamineThe metabolism of Triamterene can be decreased when combined with Fluvoxamine.
ForasartanForasartan may increase the hyperkalemic activities of Triamterene.
FosinoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Fosinopril.
FurosemideThe risk or severity of adverse effects can be increased when Triamterene is combined with Furosemide.
GuanfacineThe risk or severity of adverse effects can be increased when Triamterene is combined with Guanfacine.
HeparinHeparin may increase the hyperkalemic activities of Triamterene.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Triamterene.
HexobarbitalHexobarbital may increase the hypotensive activities of Triamterene.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Triamterene.
HydralazineThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Triamterene is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.
IbuprofenIbuprofen may decrease the antihypertensive activities of Triamterene.
IbuproxamIbuproxam may decrease the antihypertensive activities of Triamterene.
IcatibantIcatibant may decrease the antihypertensive activities of Triamterene.
IndapamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.
IndomethacinIndomethacin may decrease the antihypertensive activities of Triamterene.
IndoprofenIndoprofen may decrease the antihypertensive activities of Triamterene.
IrbesartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Irbesartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Triamterene.
IsoxsuprineThe risk or severity of adverse effects can be increased when Triamterene is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Triamterene.
KebuzoneKebuzone may decrease the antihypertensive activities of Triamterene.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Triamterene.
KetoprofenKetoprofen may decrease the antihypertensive activities of Triamterene.
KetorolacKetorolac may decrease the antihypertensive activities of Triamterene.
LabetalolThe risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Triamterene.
LevobunololThe risk or severity of adverse effects can be increased when Triamterene is combined with Levobunolol.
LevodopaTriamterene may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Triamterene.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.
LidocaineThe metabolism of Triamterene can be decreased when combined with Lidocaine.
LisinoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Triamterene.
LornoxicamLornoxicam may decrease the antihypertensive activities of Triamterene.
LosartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Losartan.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Triamterene.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Triamterene.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Triamterene.
MannitolThe risk or severity of adverse effects can be increased when Triamterene is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Triamterene.
MecamylamineThe risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Triamterene.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Triamterene.
MeloxicamMeloxicam may decrease the antihypertensive activities of Triamterene.
MesalazineMesalazine may decrease the antihypertensive activities of Triamterene.
MetamizoleMetamizole may decrease the antihypertensive activities of Triamterene.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Triamterene.
MethazolamideThe risk or severity of adverse effects can be increased when Triamterene is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Triamterene.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene.
MethyldopaThe risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Triamterene.
MetipranololThe risk or severity of adverse effects can be increased when Triamterene is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Triamterene.
MexiletineThe metabolism of Triamterene can be decreased when combined with Mexiletine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Triamterene.
MoexiprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Moexipril.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Triamterene.
NabumetoneNabumetone may decrease the antihypertensive activities of Triamterene.
NadololThe risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Triamterene.
NaftifineNaftifine may decrease the antihypertensive activities of Triamterene.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.
NaproxenNaproxen may decrease the antihypertensive activities of Triamterene.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Triamterene.
NebivololThe risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.
NepafenacNepafenac may decrease the antihypertensive activities of Triamterene.
NesiritideThe risk or severity of adverse effects can be increased when Triamterene is combined with Nesiritide.
NevirapineThe metabolism of Triamterene can be decreased when combined with Nevirapine.
NicardipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Triamterene.
NifedipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Triamterene.
NimesulideNimesulide may decrease the antihypertensive activities of Triamterene.
NimodipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.
NisoldipineThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitroglycerin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Triamterene.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Triamterene.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Triamterene.
OlopatadineOlopatadine may decrease the antihypertensive activities of Triamterene.
OlsalazineOlsalazine may decrease the antihypertensive activities of Triamterene.
OmapatrilatTriamterene may increase the hyperkalemic activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Triamterene.
OrgoteinOrgotein may decrease the antihypertensive activities of Triamterene.
OsimertinibThe serum concentration of Triamterene can be decreased when it is combined with Osimertinib.
OuabainThe therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.
OxaprozinOxaprozin may decrease the antihypertensive activities of Triamterene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Triamterene.
PapaverineThe risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Triamterene.
ParnaparinParnaparin may increase the hyperkalemic activities of Triamterene.
Peginterferon alfa-2bThe serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.
PenbutololThe risk or severity of adverse effects can be increased when Triamterene is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.
PentobarbitalPentobarbital may increase the hypotensive activities of Triamterene.
PerindoprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Triamterene.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Triamterene.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Triamterene.
PindololThe risk or severity of adverse effects can be increased when Triamterene is combined with Pindolol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Triamterene.
PiroxicamPiroxicam may decrease the antihypertensive activities of Triamterene.
PrazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Prazosin.
PrimidonePrimidone may increase the hypotensive activities of Triamterene.
PropacetamolPropacetamol may decrease the antihypertensive activities of Triamterene.
PropranololThe risk or severity of adverse effects can be increased when Triamterene is combined with Propranolol.
PTC299PTC299 may decrease the antihypertensive activities of Triamterene.
QuetiapineThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Quinapril.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Triamterene.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.
RescinnamineTriamterene may increase the hyperkalemic activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Triamterene.
ResveratrolResveratrol may decrease the antihypertensive activities of Triamterene.
ReviparinReviparin may increase the hyperkalemic activities of Triamterene.
RifampicinThe metabolism of Triamterene can be increased when combined with Rifampicin.
RiociguatThe risk or severity of adverse effects can be increased when Triamterene is combined with Riociguat.
RisperidoneTriamterene may increase the hypotensive activities of Risperidone.
RofecoxibRofecoxib may decrease the antihypertensive activities of Triamterene.
RopiniroleThe metabolism of Triamterene can be decreased when combined with Ropinirole.
SalicylamideSalicylamide may decrease the antihypertensive activities of Triamterene.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Triamterene.
SalsalateSalsalate may decrease the antihypertensive activities of Triamterene.
SaprisartanSaprisartan may increase the hyperkalemic activities of Triamterene.
SaralasinSaralasin may increase the hyperkalemic activities of Triamterene.
SecobarbitalSecobarbital may increase the hypotensive activities of Triamterene.
SeratrodastSeratrodast may decrease the antihypertensive activities of Triamterene.
SimeprevirThe metabolism of Triamterene can be decreased when combined with Simeprevir.
SotalolThe risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.
SpiraprilTriamterene may increase the hyperkalemic activities of Spirapril.
SpironolactoneTriamterene may increase the hyperkalemic activities of Spironolactone.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Triamterene.
SRT501SRT501 may decrease the antihypertensive activities of Triamterene.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Triamterene.
SulindacSulindac may decrease the antihypertensive activities of Triamterene.
SuprofenSuprofen may decrease the antihypertensive activities of Triamterene.
TacrolimusTriamterene may increase the hyperkalemic activities of Tacrolimus.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.
TasosartanTasosartan may increase the hyperkalemic activities of Triamterene.
TelmisartanThe risk or severity of adverse effects can be increased when Triamterene is combined with Telmisartan.
TemocaprilTriamterene may increase the hyperkalemic activities of Temocapril.
TenofovirThe metabolism of Triamterene can be decreased when combined with Tenofovir.
TenoxicamTenoxicam may decrease the antihypertensive activities of Triamterene.
TepoxalinTepoxalin may decrease the antihypertensive activities of Triamterene.
TerazosinThe risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.
TeriflunomideThe serum concentration of Triamterene can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Triamterene can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Triamterene.
ThiopentalThiopental may increase the hypotensive activities of Triamterene.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Triamterene.
TiclopidineThe metabolism of Triamterene can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Triamterene.
TinzaparinTinzaparin may increase the hyperkalemic activities of Triamterene.
TizanidineThe risk or severity of adverse effects can be increased when Triamterene is combined with Tizanidine.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Triamterene.
TolmetinTolmetin may decrease the antihypertensive activities of Triamterene.
TolvaptanTolvaptan may increase the hyperkalemic activities of Triamterene.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.
TrandolaprilThe risk or severity of adverse effects can be increased when Triamterene is combined with Trandolapril.
TranilastTranilast may decrease the antihypertensive activities of Triamterene.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Triamterene.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Triamterene.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.
VemurafenibThe serum concentration of Triamterene can be increased when it is combined with Vemurafenib.
VerapamilThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Triamterene.
ZileutonZileuton may decrease the antihypertensive activities of Triamterene.
ZomepiracZomepirac may decrease the antihypertensive activities of Triamterene.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1G
Uniprot ID:
P51170
Molecular Weight:
74269.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. [PubMed:12827214 ]
  4. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  5. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1A
Uniprot ID:
P37088
Molecular Weight:
75703.08 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ww domain binding
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Plays an essential role in electrolyte and blood pressure homeostasis, but also in airway surface liquid homeostasis, which is important for proper clearance of mucus. C...
Gene Name:
SCNN1B
Uniprot ID:
P51168
Molecular Weight:
72658.485 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. [PubMed:8772124 ]
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Ligand-gated sodium channel activity
Specific Function:
Sodium permeable non-voltage-sensitive ion channel inhibited by the diuretic amiloride. Mediates the electrodiffusion of the luminal sodium (and water, which follows osmotically) through the apical membrane of epithelial cells. Controls the reabsorption of sodium in kidney, colon, lung and sweat glands. Also plays a role in taste perception.
Gene Name:
SCNN1D
Uniprot ID:
P51172
Molecular Weight:
70214.195 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. [PubMed:11509829 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23